GW-3333

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H525252

CAS#: 212609-68-2

Description: GW-3333 is a tumor necrosis factor-alpha (TNF)-Converting Enzyme (TACE) inhibitor. It is also an matrix metalloproteinase inhibitor. The efficacy of GW3333 suggests that dual inhibitors of TACE and matrix metalloproteinases may prove therapeutic as antiarthritics.


Chemical Structure

img
GW-3333
CAS# 212609-68-2

Theoretical Analysis

Hodoodo Cat#: H525252
Name: GW-3333
CAS#: 212609-68-2
Chemical Formula: C22H36N4O4
Exact Mass: 420.27
Molecular Weight: 420.550
Elemental Analysis: C, 62.83; H, 8.63; N, 13.32; O, 15.22

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: GW-3333; GW3333; GW 3333;

IUPAC/Chemical Name: (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid, ((1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl)amide

InChi Key: SMZPWUUYPYYHIV-HNJRGHQBSA-N

InChi Code: InChI=1S/C22H36N4O4/c1-7-16(6)19(22(29)24-18-10-8-9-11-23-18)25-21(28)17(12-14(2)3)20(15(4)5)26(30)13-27/h8-11,13-17,19-20,30H,7,12H2,1-6H3,(H,25,28)(H,23,24,29)/t16-,17+,19-,20-/m0/s1

SMILES Code: CC[C@H](C)[C@@H](C(=O)Nc1ccccn1)NC(=O)[C@H](CC(C)C)[C@H](C(C)C)N(C=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 420.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tóth AE, Tóth A, Walter FR, Kiss L, Veszelka S, Ózsvári B, Puskás LG, Heimesaat MM, Dohgu S, Kataoka Y, Rákhely G, Deli MA. Compounds blocking methylglyoxal-induced protein modification and brain endothelial injury. Arch Med Res. 2014 Nov;45(8):753-64. doi: 10.1016/j.arcmed.2014.10.009. Epub 2014 Nov 13. PubMed PMID: 25446614.

2: Tippin TK, Hamilton G, Moore L, Beaudet EJ, Jolley S, Brodie TA, Andrews RC, Becherer JD, McDougald DL, Gaul MD, Hoivik DJ, Mellon-Kusibab K, Lehmann J, Kliewer S, Novick S, Laethem R, Zhao Z, LeCluyse EL. CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans. Drug Metab Dispos. 2003 Jul;31(7):870-7. PubMed PMID: 12814963.

3: Doggrell SA. TACE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs. 2002 Jul;11(7):1003-6. PubMed PMID: 12084010.

4: Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). J Med Chem. 2001 Nov 22;44(24):4252-67. PubMed PMID: 11708926.

5: Conway JG, Andrews RC, Beaudet B, Bickett DM, Boncek V, Brodie TA, Clark RL, Crumrine RC, Leenitzer MA, McDougald DL, Han B, Hedeen K, Lin P, Milla M, Moss M, Pink H, Rabinowitz MH, Tippin T, Scates PW, Selph J, Stimpson SA, Warner J, Becherer JD. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther. 2001 Sep;298(3):900-8. PubMed PMID: 11504783.